| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
3 companies
Karabelas Argeris N is a Director, 10% Owner at RCKT, with reported holdings spanning 3 companies. Recent filings cover 2 purchases and 8 sales.
Our model assigns Karabelas Argeris N a strong insider score of 73/100, based on 5 past trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +24.6%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 1, 2024 | RGNX Regenxbio Inc. | Director | Sale+OE10b5-1 | 10,000 | $10.11 | $101,052.00 | -47.0% | -29.2% | -4.3% | |
| Sep 3, 2024 | RGNX Regenxbio Inc. | Director | Sale+OE10b5-1 | 10,000 | $11.56 | $115,588.00 | -47.0% | -11.8% | -13.1% | |
| Aug 1, 2024 | RGNX Regenxbio Inc. | Director | Sale+OE10b5-1 | 10,100 | $13.51 | $136,454.00 | -47.2% | -33.6% | -38.5% | |
| Jul 29, 2024 | RGNX Regenxbio Inc. | Director | Sale+OE10b5-1 | 11,000 | $15.05 | $165,495.00 | -49.4% | -34.6% | -41.4% | |
| Jul 1, 2024 | RGNX Regenxbio Inc. | Director | Sale+OE10b5-1 | 10,000 | $11.27 | $112,691.00 | -47.0% | -5.2% | -25.7% | |
| Aug 11, 2016 | BHC Bausch Health Companies Inc. | Director | Buy | 4,000 | $24.65 | $98,600.00 | +23.9% | - | - | |
| Feb 23, 2015 | RCKT Rocket Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 603,832 | $6.00 | $3,622,992.00 | +36.1% | - | - |